Free Trial
NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.47
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
REPH stock logo

About Recro Pharma Stock (NASDAQ:REPH)

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

REPH Stock News Headlines

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
Heard about the 72-Hour Profit Surge? Read this…
One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
Heard about the 72-Hour Profit Surge? Read this…
One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…
Societal CDMO Inc
Is Recro Pharma (REPH) a Worthy Investment?
Recap: Recro Pharma Q4 Earnings
See More Headlines
Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2022
Today
7/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REPH
Employees
185
Year Founded
N/A

Profitability

Net Income
$-11,370,000.00
Pretax Margin
-15.09%

Debt

Sales & Book Value

Annual Sales
$75.36 million
Book Value
$0.90 per share

Miscellaneous

Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives


REPH Stock Analysis - Frequently Asked Questions

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) announced its earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return on equity of 56.66%.

What other stocks do shareholders of Recro Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include TherapeuticsMD (TXMD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), Nabriva Therapeutics (NBRV) and SCYNEXIS (SCYX).

This page (NASDAQ:REPH) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners